These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 35877038)

  • 21. Effects of Cardiac Resynchronization Therapy on Cardiac Remodeling and Contractile Function: Results From Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE).
    St John Sutton M; Cerkvenik J; Borlaug BA; Daubert C; Gold MR; Ghio S; Chirinos JA; Linde C; Ky B
    J Am Heart Assoc; 2015 Sep; 4(9):e002054. PubMed ID: 26363005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo.
    Westermann D; Becher PM; Lindner D; Savvatis K; Xia Y; Fröhlich M; Hoffmann S; Schultheiss HP; Tschöpe C
    Basic Res Cardiol; 2012 Nov; 107(6):308. PubMed ID: 23117837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of AKAP150 promotes pathological remodelling and heart failure propensity by disrupting calcium cycling and contractile reserve.
    Li L; Li J; Drum BM; Chen Y; Yin H; Guo X; Luckey SW; Gilbert ML; McKnight GS; Scott JD; Santana LF; Liu Q
    Cardiovasc Res; 2017 Feb; 113(2):147-159. PubMed ID: 27856611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Degree of Cardiac Remodelling before Overload Relief Triggers Different Transcriptome and miRome Signatures during Reverse Remodelling (RR)-Molecular Signature Differ with the Extent of RR.
    Rodrigues PG; Miranda-Silva D; Li X; Sousa-Mendes C; Martins-Ferreira R; Elbeck Z; Leite-Moreira AF; Knöll R; Falcão-Pires I
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33353134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathophysiology of heart failure following myocardial infarction.
    Struthers AD
    Heart; 2005 May; 91 Suppl 2(Suppl 2):ii14-6; discussion ii31, ii43-8. PubMed ID: 15831601
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiac inflammation and fibrosis following chemo/radiation therapy: mechanisms and therapeutic agents.
    Yang R; Tan C; Najafi M
    Inflammopharmacology; 2022 Feb; 30(1):73-89. PubMed ID: 34813027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-fibrotic Actions of Roselle Extract in Rat Model of Myocardial Infarction.
    Ali SS; Mohamed SFA; Rozalei NH; Boon YW; Zainalabidin S
    Cardiovasc Toxicol; 2019 Feb; 19(1):72-81. PubMed ID: 30128816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Empagliflozin prevents doxorubicin-induced myocardial dysfunction.
    Sabatino J; De Rosa S; Tammè L; Iaconetti C; Sorrentino S; Polimeni A; Mignogna C; Amorosi A; Spaccarotella C; Yasuda M; Indolfi C
    Cardiovasc Diabetol; 2020 May; 19(1):66. PubMed ID: 32414364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of the vascular endothelial sodium channel activation in the genesis of pathologically increased cardiovascular stiffness.
    Hill MA; Jaisser F; Sowers JR
    Cardiovasc Res; 2022 Jan; 118(1):130-140. PubMed ID: 33188592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PBI-4050 reduces pulmonary hypertension, lung fibrosis, and right ventricular dysfunction in heart failure.
    Nguyen QT; Nsaibia MJ; Sirois MG; Calderone A; Tardif JC; Fen Shi Y; Ruiz M; Daneault C; Gagnon L; Grouix B; Laurin P; Dupuis J
    Cardiovasc Res; 2020 Jan; 116(1):171-182. PubMed ID: 30753422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fibrosis and heart failure.
    Segura AM; Frazier OH; Buja LM
    Heart Fail Rev; 2014 Mar; 19(2):173-85. PubMed ID: 23124941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A mouse model of reverse cardiac remodelling following banding-debanding of the ascending aorta.
    Bjørnstad JL; Skrbic B; Sjaastad I; Bjørnstad S; Christensen G; Tønnessen T
    Acta Physiol (Oxf); 2012 May; 205(1):92-102. PubMed ID: 21974781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A gene therapeutic approach to inhibit calcium and integrin binding protein 1 ameliorates maladaptive remodelling in pressure overload.
    Grund A; Szaroszyk M; Döppner JK; Malek Mohammadi M; Kattih B; Korf-Klingebiel M; Gigina A; Scherr M; Kensah G; Jara-Avaca M; Gruh I; Martin U; Wollert KC; Gohla A; Katus HA; Müller OJ; Bauersachs J; Heineke J
    Cardiovasc Res; 2019 Jan; 115(1):71-82. PubMed ID: 29931050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NADPH oxidases and cardiac remodelling.
    Nabeebaccus A; Zhang M; Shah AM
    Heart Fail Rev; 2011 Jan; 16(1):5-12. PubMed ID: 20658317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased passive stiffness promotes diastolic dysfunction despite improved Ca2+ handling during left ventricular concentric hypertrophy.
    Røe ÅT; Aronsen JM; Skårdal K; Hamdani N; Linke WA; Danielsen HE; Sejersted OM; Sjaastad I; Louch WE
    Cardiovasc Res; 2017 Aug; 113(10):1161-1172. PubMed ID: 28472418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hesperetin protects against cardiac remodelling induced by pressure overload in mice.
    Deng W; Jiang D; Fang Y; Zhou H; Cheng Z; Lin Y; Zhang R; Zhang J; Pu P; Liu Y; Bian Z; Tang Q
    J Mol Histol; 2013 Oct; 44(5):575-85. PubMed ID: 23719775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation of adverse remodelling by osteopontin in a genetic heart failure model.
    Psarras S; Mavroidis M; Sanoudou D; Davos CH; Xanthou G; Varela AE; Panoutsakopoulou V; Capetanaki Y
    Eur Heart J; 2012 Aug; 33(15):1954-63. PubMed ID: 21525025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of the structural remodelling of the myocardium: from hypertrophy to heart failure.
    Brilla CG; Maisch B
    Eur Heart J; 1994 Dec; 15 Suppl D():45-52. PubMed ID: 7713113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology.
    Tarone G; Balligand JL; Bauersachs J; Clerk A; De Windt L; Heymans S; Hilfiker-Kleiner D; Hirsch E; Iaccarino G; Knöll R; Leite-Moreira AF; Lourenço AP; Mayr M; Thum T; Tocchetti CG
    Eur J Heart Fail; 2014 May; 16(5):494-508. PubMed ID: 24639064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deficiency of senescence marker protein 30 exacerbates angiotensin II-induced cardiac remodelling.
    Misaka T; Suzuki S; Miyata M; Kobayashi A; Shishido T; Ishigami A; Saitoh S; Hirose M; Kubota I; Takeishi Y
    Cardiovasc Res; 2013 Aug; 99(3):461-70. PubMed ID: 23723062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.